Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alkem Laboratories Limited (ALKEM.NS)
INR5,659.00
+57.50 (+1.03%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Devashish Building 400013
Mumbai, IN
Mumbai, IN
CEO
Vikas Gupta
Website
alkemlabs.com
IPO
2015-12-23
ISIN INE540L01014
Also trades on
Bombay Stock Exchange · ALKEM.BO (INR)
National Stock Exchange of India · ALKEM.NS (INR)
Description
Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and nutraceuticals. These products target both immediate and chronic health issues across numerous therapeutic areas, including anti-infectives, skin conditions, cardiovascular health, respiratory ailments, digestive problems, central nervous system disorders, cancer, urology, and women's health. The company also provides essential vitamins, minerals, and nutritional supplements, in addition to pain relief medications, anti-diabetic treatments, and neurological remedies. Complementing its core pharmaceutical lines, Alkem offers consumer health items such as pregnancy detection kits and condoms. Founded in 1973, the company's headquarters are located in Mumbai, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR5,659.00
+57.50 (+1.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
144.9K
Beta
0.27
Float Shares
39.18M
Free Float %
32.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.77% | -0.99% | +1.04% | -2.92% | -3.69% | -0.57% | +4.00% | +63.51% | +85.14% | +328.81% | +296.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5,659.00
DCF (Unlevered)
7,249.53
+28.1%
DCF (Levered)
6,874.15
+21.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
52% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 5 | 0 |
| Hold | 7 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.63
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.9% ★ Q1'26: +14.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+6.3% Q1'26: -22.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.2% Q1'26: +12.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.6% ★ Q1'26: +13.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+21.8% ★ Q1'26: +10.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.60× ★ Q1'26: 0.88× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 19 Rev. Ana. 14 EPS Ana. |
Mar 2027 19 Rev. Ana. 19 EPS Ana. |
Mar 2028 18 Rev. Ana. 17 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
48.65B
est: 50.62B (-3.9%)
|
56.16B
est: 59.02B (-4.8%)
|
63.04B
est: 63.85B (-1.3%)
|
72.66B
est: 72.99B (-0.5%)
|
81.92B
est: 82.57B (-0.8%)
|
87.28B
est: 89.48B (-2.5%)
|
105.12B
est: 105.56B (-0.4%)
|
114.40B
est: 114.77B (-0.3%)
|
124.39B
est: 127.32B (-2.3%)
|
128.05B
est: 130.26B (-1.7%)
|
145.88B
144.60B – 147.08B
+12.0% YoY
|
162.54B
147.84B – 169.20B
+11.4% YoY
|
179.36B
179.19B – 179.53B
+10.3% YoY
|
| EBITDA |
10.89B
est: 10.38B (+4.9%)
|
11.05B
est: 12.41B (-11.0%)
|
11.19B
est: 12.22B (-8.4%)
|
11.98B
est: 12.41B (-3.5%)
|
15.67B
est: 12.91B (+21.3%)
|
21.66B
est: 16.07B (+34.8%)
|
21.89B
est: 17.71B (+23.6%)
|
17.09B
est: 19.90B (-14.1%)
|
24.18B
est: 26.28B (-8.0%)
|
29.71B
est: 27.16B (+9.4%)
|
30.12B
29.85B – 30.36B
+10.9% YoY
|
33.55B
30.52B – 34.93B
+11.4% YoY
|
37.03B
36.99B – 37.06B
+10.3% YoY
|
| EBIT |
9.96B
est: 8.99B (+10.8%)
|
10.03B
est: 9.29B (+8.0%)
|
9.76B
est: 9.77B (0.0%)
|
10.04B
est: 10.16B (-1.2%)
|
13.14B
est: 10.98B (+19.7%)
|
18.91B
est: 13.98B (+35.2%)
|
18.85B
est: 15.41B (+22.3%)
|
13.99B
est: 17.32B (-19.2%)
|
21.19B
est: 22.73B (-6.8%)
|
26.14B
est: 23.49B (+11.3%)
|
26.05B
25.82B – 26.26B
+10.9% YoY
|
29.02B
26.40B – 30.21B
+11.4% YoY
|
32.02B
31.99B – 32.05B
+10.3% YoY
|
| Net Income |
7.42B
est: 7.91B (-6.3%)
|
8.92B
est: 8.67B (+2.9%)
|
6.31B
est: 9.68B (-34.8%)
|
7.61B
est: 7.19B (+5.8%)
|
11.27B
est: 8.69B (+29.7%)
|
15.85B
est: 12.25B (+29.4%)
|
16.46B
est: 13.50B (+21.9%)
|
9.84B
est: 11.43B (-13.9%)
|
17.96B
est: 20.54B (-12.6%)
|
21.65B
est: 22.85B (-5.2%)
|
25.13B
24.57B – 26.71B
+10.0% YoY
|
22.77B
19.10B – 28.44B
-9.4% YoY
|
26.54B
22.77B – 32.83B
+16.6% YoY
|
| SGA |
11.70B
est: 7.44B (+57.3%)
|
13.91B
est: 22.43B (-38.0%)
|
16.56B
est: 24.44B (-32.3%)
|
18.73B
est: 29.95B (-37.5%)
|
20.85B
est: 35.23B (-40.8%)
|
19.81B
est: 35.97B (-44.9%)
|
25.77B
est: 39.64B (-35.0%)
|
29.73B
est: 44.54B (-33.3%)
|
30.32B
est: 31.29B (-3.1%)
|
32.42B
est: 32.34B (+0.3%)
|
35.85B
35.54B – 36.15B
+10.9% YoY
|
39.95B
36.34B – 41.59B
+11.4% YoY
|
44.08B
44.04B – 44.12B
+10.3% YoY
|
| EPS |
62.02
est: 66.18 (-6.3%)
|
74.61
est: 77.59 (-3.8%)
|
52.77
est: 64.82 (-18.6%)
|
63.61
est: 68.31 (-6.9%)
|
94.26
est: 94.24 (+0.0%)
|
132.57
est: 137.63 (-3.7%)
|
137.63
est: 149.87 (-8.2%)
|
82.31
est: 106.37 (-22.6%)
|
150.19
est: 171.81 (-12.6%)
|
181.11
est: 182.50 (-0.8%)
|
212.05
205.50 – 223.37
+16.2% YoY
|
188.66
159.77 – 237.88
-11.0% YoY
|
220.68
190.47 – 274.57
+17.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
7.93B
OE per share TTM
66.29
Owner's Yield
1.22%
Maintenance CapEx ratio
33.13%
Maint CapEx / Avg PPE
24.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Rayliant Wilshire NxtGen Emerging Markets Equity ETF RWEM | 0.26% | 203.3K | 0.52% |
| 2 | WisdomTree India Earnings Fund EPI | 0.09% | 1.80M | 0.84% |
| 3 | WisdomTree Emerging Markets Quality Dividend Growth Fund DGRE | 0.08% | 116.7K | 0.32% |
| 4 | WisdomTree True Emerging Markets Fund XC | 0.06% | 50.2K | 0.32% |
| 5 | WisdomTree Emerging Markets ex-State-Owned Enterprises UCITS ETF - USD Acc XSOE.L | 0.04% | 8.6K | 0.32% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.04% | 219.9K | 0.44% |
| 7 | WisdomTree Emerging Markets ex-State-Owned Enterprises Fund XSOE | 0.03% | 621.2K | 0.32% |
| 8 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.02% | 78.6K | 0.56% |
| 9 | Schwab Emerging Markets Equity ETF SCHE | 0.02% | 2.98M | 0.06% |
| 10 | State Street SPDR MSCI Emerging Markets Fossil Fuel Reserves Free ETF EEMX | 0.02% | 38.3K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.74M
Shares Outstanding
119.57M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Basudeo Narian Singh | Executive Chairman | 214M | male |
| Madhurima Singh | Executive Director | 124M | female |
| Srinivas Singh | Executive Director | 124M | male |
| Mritunjay Kumar Singh | Executive Director | 124M | male |
| Sandeep Derjit Singh | MD & Executive Director | 98M | male |
| Nitin Agrawal | Chief Financial Officer & President of Finance | 22M | male |
| Vikas Gupta | Chief Executive Officer | — | — |
| Rajorshi Ganguli | President & Global HR Head | — | male |
| Shirish Purushotham Ambulgekar | President & Global Quality Head | — | male |
| Akhilesh D. Sharma | President & Chief Medical Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALKEM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
